Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Stemline Therapeutics, Inc. (NASDAQ: STML).

Full DD Report for STML

You must become a subscriber to view this report.


Recent News from (NASDAQ: STML)

Stemline Therapeutics to Present at the H.C. Wainwright 20th Annual Global Investment Conference
NEW YORK, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that Ivan Bergstein, M.D., Stemline’s CEO, will present at the H.C. Wainwright 20 th Annual Glo...
Source: GlobeNewswire
Date: September, 05 2018 07:00
How Stemline's Latest Catalyst Shifts The Investment Thesis
2018 has been no stranger to exciting developments in biotech, what with the first approvals for RNAi technology, emerging gene therapies, and treatment options for rare forms of cancer. In particular, for me, it's been a banner year for several companies going it on their own in the develop...
Source: SeekingAlpha
Date: August, 15 2018 03:13
Your Daily Pharma Scoop: Redhill Receives NoA, Regeneron Gets CRL, Stemline NDA Under Review
Stocks in News: RDHL, REGN RedHill Bio nabs U.S. patent covering RHB-104 and RHB-204 Discussion : RedHill Biopharma ( RDHL ) received a Notice of Allowance for its new formulation covering RHB-104 in Crohn's disease and RHB-204 in pulmonary nontuberculous mycobacteria infections. The ...
Source: SeekingAlpha
Date: August, 14 2018 08:58
3 Things In Biotech, August 14: Is Stemline Finally A Go In Cancer?
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. AstraZeneca goes to the home stretch for their updated label in COPD Company: AstraZene...
Source: SeekingAlpha
Date: August, 14 2018 08:00
Stemline Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference
NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that Ivan Bergstein, M.D., Stemline’s CEO, will present at the 2018 Wedbush PacGrow Healthcare Co...
Source: GlobeNewswire
Date: August, 14 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-1416.5516.7516.8016.35162,410
2017-03-108.909.459.558.9086,900
2017-03-098.158.808.857.90655,024
2017-03-088.208.158.308.05208,037
2017-03-078.508.008.557.90340,547

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1022,77938,80958.6951Short
2018-12-0719,41056,47334.3704Cover
2018-12-0627,804105,15026.4422Cover
2018-12-0464,976467,74413.8914Cover
2018-12-0354,147327,66316.5252Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on STML.


About Stemline Therapeutics, Inc. (NASDAQ: STML)

Logo for Stemline Therapeutics, Inc. (NASDAQ: STML)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: STML)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: August, 13 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: August, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: August, 09 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: August, 09 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: July, 02 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: June, 26 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: June, 22 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 10 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 10 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 30 2018

       

       


      Daily Technical Chart for (NASDAQ: STML)

      Daily Technical Chart for (NASDAQ: STML)


      Stay tuned for daily updates and more on (NASDAQ: STML)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: STML)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in STML is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of STML and does not buy, sell, or trade any shares of STML. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/